The work presented here supports for the idea that targeting BRG1 in breast cancer and in other cancers such as melanoma and colorectal, gastric, and prostate cancer [84–88] could be therapeutic via mechanisms that reduce cell proliferation and increase chemosensitivity. Here, SMARCA4 is linked to prostate carcinoma.